RNAi-BASED THERAPEUTICS FOR ALLERGIC RHINITIS AND ASTHMA
    10.
    发明申请
    RNAi-BASED THERAPEUTICS FOR ALLERGIC RHINITIS AND ASTHMA 审中-公开
    用于过敏性RHINITIS和ASTHMA的基于RNAi的治疗方法

    公开(公告)号:US20110112169A1

    公开(公告)日:2011-05-12

    申请号:US12891626

    申请日:2010-09-27

    摘要: The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and/or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent/delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.

    摘要翻译: 本发明提供包含用于治疗由(例如,特征为IgE介导的超敏反应)介导的病症和疾病的一种或多种RNAi剂(例如siRNA,shRNA或RNAi载体)的组合物,以及用于鉴定有效的RNAi剂的系统 以此目的。 该组合物适用于治疗过敏性鼻炎和/或哮喘。 在本发明的某些实施方案中,所述R​​NAi试剂靶向编码选自下组的蛋白质的转录物:FC&RIα链,FC& RI&bgr; 链,c-Kit,Lyn,Syk,ICOS,OX40L,CD40,CD80,CD86,Re1A,Re1B,4-1BB配体,TLR1,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,CD83,SLAM ,普通γ链和COX-2。 此外,本发明提供RNAi剂/递送剂组合物和使用方法。 在本发明的某些实施方案中,包含RNAi试剂的组合物通过呼吸途径递送。